Novel therapeutic targets for autism

Trends in Pharmacological Sciences

Volumn 29, Issue 8, 2008, Pages 375-382

  Theoharides, Theoharis C ^a,b   Doyle, Robert ^c   Francis, Konstantinos ^b   Conti, Pio ^d   Kalogeromitros, Dimitris ^b  

^a Department of Pharmacology and Experimental Therapeutics   (United States)

^b IASO GENERAL HOSPITAL   (Greece)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CHONDROITIN SULFATE; COMPOUND 48-80; CROMOGLYCATE DISODIUM; CYPROHEPTADINE; FC RECEPTOR IIB; FLAVONOID; HALOPERIDOL; HISTAMINE RELEASE INHIBITOR; QUERCETIN; SEROTONIN; SEROTONIN ANTAGONIST;

ARTICLE; AUTISM; AWARENESS; BLOOD BRAIN BARRIER; CELL ACTIVATION; DISEASE ASSOCIATION; FOOD ALLERGY; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRACT FUNCTION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAST CELL; MASTOCYTOSIS; MEMBRANE PERMEABILITY; NUTRITIONAL INTOLERANCE; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; SIDE EFFECT; SOCIAL ADAPTATION; STEREOTYPY; TACHYPHYLAXIS;

ADOLESCENT; ADULT; AUTISTIC DISORDER; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MAST CELLS; MIDDLE AGED;

EID: 48049111366     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2008.06.002     Document Type: Article

References (69)

1. Johnson C.P., and Myers S.M. Identification and evaluation of children with autism spectrum disorders. Pediatrics 120 (2007) 1183-1215
2. Yeargin-Allsopp M., et al. Prevalence of autism in a US metropolitan area. J. Am. Med. Assoc. 289 (2003) 49-55
3. Gurney J.G., et al. Parental report of health conditions and health care use among children with and without autism: National Survey of Children's Health. Arch. Pediatr. Adolesc. Med. 160 (2006) 825-830
4. Baker J.P. Mercury, vaccines, and autism: one controversy, three histories. Am. J. Public Health 98 (2008) 244-253
5. Fombonne E. Thimerosal disappears but autism remains. Arch. Gen. Psychiatry 65 (2008) 15-16
6. Theoharides T.C., and Kalogeromitros D. The critical role of mast cell in allergy and inflammation. Ann. N. Y. Acad. Sci. 1088 (2006) 78-99
7. Theoharides T.C., and Konstantinidou A. Corticotropin-releasing hormone and the blood-brain-barrier. Front. Biosci. 12 (2007) 1615-1628
8. Levy S.E., et al. Relationship of dietary intake to gastrointestinal symptoms in children with autistic spectrum disorders. Biol. Psychiatry 61 (2007) 492-497
9. Black C., et al. Relation of childhood gastrointestinal disorders to autism: nested case-control study using data from the UK General Practice Research Database. BMJ 325 (2002) 419-421
10. MacDonald T.T., and Domizio P. Autistic enterocolitis; is it a histopathological entity?. Histopathology 50 (2007) 371-379
11. Liu Z., et al. Tight junctions, leaky intestines, and pediatric diseases. Acta Paediatr. 94 (2005) 386-393
12. Venter C., et al. Prevalence and cumulative incidence of food hypersensitivity in the first 3 years of life. Allergy 63 (2008) 354-359
13. Teufel M., et al. Psychological burden of food allergy. World J. Gastroenterol. 13 (2007) 3456-3465
14. Ortolani C., and Pastorello E.A. Food allergies and food intolerances. Best Pract. Res. Clin. Gastroenterol. 20 (2006) 467-483
15. Hadjivassiliou M., et al. The immunology of gluten sensitivity: beyond the gut. Trends Immunol. 25 (2004) 578-582
16. Vojdani A. Antibodies as predictors of complex autoimmune diseases. Int. J. Immunopath. Pharmacol. 21 (2008) 267-278
17. Elder J.H., et al. The gluten-free, casein-free diet in autism: results of a preliminary double blind clinical trial. J. Autism Dev. Disord. 36 (2006) 413-420
18. Lucarelli S., et al. Food allergy and infantile autism. Panminerva Med. 37 (1995) 137-141
19. Vojdani A., et al. Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J. Neuroimmunol. 129 (2002) 168-177
20. Gillott A., and Standen P.J. Levels of anxiety and sources of stress in adults with autism. J. Intellect. Disabil. 11 (2007) 359-370
21. Jansen L.M., et al. Differentiation between autism and multiple complex developmental disorder in response to psychosocial stress. Neuropsychopharmacology 28 (2003) 582-590
22. Tani P., et al. Higher plasma ACTH levels in adults with Asperger syndrome. J. Psychosom. Res. 58 (2005) 533-536
23. Theoharides T.C., et al. Stress-induced rat intestinal mast cell intragranular activation and inhibitory effect of sulfated proteoglycans. Dig. Dis. Sci. 44 (1999) 87S-93S
24. Galli S.J., et al. Mast cells as 'tunable' effector and immunoregulatory cells: recent advances. Annu. Rev. Immunol. 23 (2005) 749-786
25. Bachelet I., and Levi-Schaffer F. Mast cells as effector cells: a co-stimulating question. Trends Immunol. 28 (2007) 360-365
26. Theoharides T.C., and Cochrane D.E. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J. Neuroimmunol. 146 (2004) 1-12
27. Abbott N.J. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell. Mol. Neurobiol. 20 (2000) 131-147
28. Chez M.G., et al. Elevation of tumor necrosis factor-α in cerebrospinal fluid of autistic children. Pediatr. Neurol. 36 (2007) 361-365
29. Reichenberg A., et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry 58 (2001) 445-452
30. Jyonouchi H., et al. Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention. Neuropsychobiology 51 (2005) 77-85
31. Yao Y., et al. Altered vascular phenotype in autism: correlation with oxidative stress. Arch. Neurol. 63 (2006) 1161-1164
32. Farhadi A., et al. Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: stress, intestinal hyperpermeability and inflammation. World J. Gastroenterol. 13 (2007) 3027-3030
33. Rijnierse A., et al. Mast cells and nerves tickle in the tummy. Implications for inflammatory bowel disease and irritable bowel syndrome. Pharmacol. Ther. 116 (2007) 207-235
34. Esposito P., et al. Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J. Pharmacol. Exp. Ther. 303 (2002) 1061-1066
35. Matsumoto I., et al. Brain mast cells act as an immune gate to the hypothalamic-pituitary-adrenal axis in dogs. J. Exp. Med. 194 (2001) 71-78
36. Theoharides T.C., et al. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol. Sci. 25 (2004) 563-568
37. Crompton R., et al. Corticotropin-releasing hormone causes vasodilation in human skin via mast cell-dependent pathways. J. Clin. Endocrinol. Metab. 88 (2003) 5427-5432
38. Castagliuolo I., et al. Acute stress causes mucin release from rat colon: role of corticotropin releasing factor and mast cells. Am. J. Physiol. 271 (1996) 884-892
39. Wallon C., et al. Corticotropin releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 57 (2008) 50-58
40. Paus R., et al. Neuroimmunoendocrine circuitry of the 'brain-skin connection'. Trends Immunol. 27 (2006) 32-39
41. Castells M., and Austen K.F. Mastocytosis: mediator-related signs and symptoms. Int. Arch. Allergy Immunol. 127 (2002) 147-152
42. Akin C., et al. Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment. Curr. Allergy Asthma Rep. 6 (2006) 282-288
43. Comi A.M., et al. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J. Child Neurol. 14 (1999) 388-394
44. Croen L.A., et al. Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. Arch. Pediatr. Adolesc. Med. 159 (2005) 151-157
45. Menage P., et al. An IgE mechanism in autistic hypersensitivity?. Biol. Psychiatry 31 (1992) 210-212
46. Bakkaloglu B., et al. Atopic features in early childhood autism. Eur. J Paediatr. Neurol (2008). http://www.sciencedirect.com 10.1016/j.ejpn.2007.12.008
47. Theoharides T.C., et al. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol. Rev. 217 (2007) 65-78
48. Kandere-Grzybowska K., et al. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J. Immunol. 171 (2003) 4830-4836
49. Theoharides T.C., et al. Brain cytokines and neuropsychiatric disorders. J. Clin. Psychopharmacol. 24 (2004) 577-581
50. Cao J., et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J. Immunol. 174 (2005) 7665-7675
51. Abdel-Majid R.M., and Marshall J.S. Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. J. Immunol. 172 (2004) 1227-1236
52. Varadaradjalou S., et al. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur. J. Immunol. 33 (2003) 899-906
53. McCurdy J.D., et al. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J. Immunol. 170 (2003) 1625-1629
54. Kulka M., et al. Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. J. Allergy Clin. Immunol. 114 (2004) 174-182
55. Arvola T., et al. Rectal bleeding in infancy: clinical, allergological, and microbiological examination. Pediatrics 117 (2006) e760-e768
56. Broadstock M., et al. Systematic review of the effectiveness of pharmacological treatments for adolescents and adults with autism spectrum disorder. Autism 11 (2007) 335-348
57. Hranilovic D., et al. Hyperserotonemia in adults with autistic disorder. J. Autism Dev. Disord. 37 (2007) 1934-1940
58. Akhondzadeh S., et al. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. J. Clin. Pharm. Ther. 29 (2004) 145-150
59. De Giorgio R., et al. Novel therapeutic targets for enteric nervous system disorders. Trends Pharmacol. Sci. 28 (2007) 473-481
60. Swindle E.J., and Metcalfe D.D. The role of reactive oxygen species and nitric oxide in mast cell-dependent inflammatory processes. Immunol. Rev. 217 (2007) 186-205
61. James, S., J. et al. (2006) Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 141, 947-956.
62. James S.J., et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am. J. Clin. Nutr. 80 (2004) 1611-1617
63. Malbec O., and Daëron M. The mast cell IgG receptors and their roles in tissue inflammation. Immunol. Rev. 217 (2007) 206-221
64. Theoharides T.C., et al. Chondroitin sulfate inhibits connective tissue mast cells. Br. J. Pharmacol. 131 (2000) 1039-1049
65. Middleton Jr. E., et al. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol. Rev. 52 (2000) 673-751
66. Kempuraj D., et al. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br. J. Pharmacol. 145 (2005) 934-944
67. Gravanis A., and Margioris A.N. The corticotropin-releasing factor (CRF) family of neuropeptides in inflammation: potential therapeutic applications. Curr. Med. Chem. 12 (2005) 1503-1512
68. Martinez V., and Tache Y. CRF1 receptors as a therapeutic target for irritable bowel syndrome. Curr. Pharm. Des. 12 (2006) 4071-4088
69. Bruijnzeel-Koomen C., et al. Adverse reactions to food. European Academy of Allergology and Clinical Immunology Subcommittee. Allergy 50 (1995) 623-635